-
01.28.2026 | Wellcome renews AMR innovation partnership with CARB-X with US$60M award
CARB-X announced today its renewed partnership with Wellcome, a global charitable foundation which co-founded CARB-X in 2016. Between 2026 and 2028, Wellcome will provide CARB-X with new funding of up to US$60 million to support early-stage research and development of innovative antibacterial products to protect lives from bacterial infections globally.
-
01.08.2026 | CARB-X announces new chemistry-focused theme ahead of 2026 funding call
CARB-X is seeking applications for novel chemistry plans against known antimicrobial resistance (AMR) targets. The aim is to unlock innovative starting points for therapeutics to address dangerous, drug-resistant bacterial infections.
Toggle navigation